文献速递肝病

系统综述:慢性病毒性肝炎与代谢紊乱

Systematic review: chronic viral hepatitis and metabolic derangement.
PubMed 文献 · Aliment Pharmacol Ther · 2019-11-20

该综述检索PubMed文献,总结乙肝病毒(HBV)和丙肝病毒(HCV)感染与代谢综合征(MetS)及其组分的相互作用。HCV感染与高脂血症负相关、与胰岛素抵抗及2型糖尿病风险正相关;HBV感染可能保护免于MetS和肝脂肪变。合并代谢疾病的病毒性肝炎患者应接受多学科管理。

要点

  • HCV感染与高脂血症负相关,持续病毒应答后出现血脂反弹。
  • HCV感染与胰岛素抵抗、肝脂肪变、MetS及2型糖尿病风险正相关。
  • HBV感染可能保护免于MetS和肝脂肪变,与胰岛素抵抗无确定关联。

核心结论

  • HCV感染与高脂血症负相关,与胰岛素抵抗、肝脂肪变、MetS及2型糖尿病风险正相关。
  • HBV感染可能保护免于MetS和肝脂肪变,与胰岛素抵抗或2型糖尿病风险无确定关联。
  • 病毒性肝炎合并代谢疾病患者应接受多学科管理而非单纯抗病毒治疗。

研究设计与样本

  • 系统综述,检索PubMed中关于HBV、HCV感染、MetS、脂肪肝及其组分的文献。

主要发现

  • HCV感染中脂质是病毒进入肝细胞的重要介导因素,HBV感染中则不是。
  • HCV感染与高脂血症负相关,干扰素为基础治疗或直接抗病毒药物诱导持续病毒应答后出现血脂反弹。
  • HCV感染与胰岛素抵抗、肝脂肪变、MetS及2型糖尿病和动脉粥样硬化风险正相关。
  • HBV感染可能保护感染对象免于MetS和肝脂肪变,与脂代谢负相关,与胰岛素抵抗或2型糖尿病及动脉硬化风险无确定关联。

临床怎么用

  • 对病毒性肝炎合并代谢疾病患者,应采用多学科方法管理,而非仅抗病毒治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The liver has a critical role in the metabolism of glucose and lipids. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection leads to a spectrum of liver disease including chronic hepatitis, cirrhosis and hepatocellular carcinoma. Metabolic syndrome (MetS) has a rising incidence owing to an epidemic of type 2 diabetes mellitus (T2DM) and obesity. Non-alcoholic fatty liver disease is a liver manifestation of MetS and has become the most common cause of chronic liver disease worldwide. AIM: To summarise the interplay among hepatitis viruses, MetS and its components. METHODS: We searched the literature about HBV, HCV infection, MetS, fatty liver and its components from PubMed. RESULTS: With respect to the viral replication cycle, lipids are important mediators between viral entry and hepatocyte in HCV infection, but not in HBV infection. Thus, HCV infection is inversely associated with hyperlipidaemia and lipid rebound occurs following sustained viral response induced by interferon-based therapy or direct antiviral agents. In addition, HCV infection is positively associated with insulin resistance, hepatic steatosis, MetS and the risk of T2DM and atherosclerosis. In contrast, HBV infection may protect infected subjects from the development of MetS and hepatic steatosis. Accumulating evidence suggests that HBV infection is inversely associated with lipid metabolism, and exhibits no conclusive association with insulin resistance or the risk of T2DM and arteriosclerosis. CONCLUSIONS: In patients with viral hepatitis and concurrent metabolic diseases, a multidisciplinary approach should be given rather than simply antiviral treatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang CC, Cheng PN, Kao JH, et al. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2019. PMID: 31746482. doi:10.1111/apt.15575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。